 Stephen Keysar
Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 18 | 2024 | 544 | 2.810 |
Why?
| | Neoplastic Stem Cells | 9 | 2022 | 378 | 2.050 |
Why?
| | Carcinoma, Squamous Cell | 12 | 2022 | 627 | 1.800 |
Why?
| | Xenograft Model Antitumor Assays | 15 | 2024 | 808 | 0.830 |
Why?
| | Biomarkers, Tumor | 5 | 2021 | 1164 | 0.740 |
Why?
| | SOXB1 Transcription Factors | 3 | 2021 | 57 | 0.730 |
Why?
| | CD59 Antigens | 4 | 2009 | 20 | 0.670 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 44 | 0.650 |
Why?
| | ErbB Receptors | 5 | 2022 | 607 | 0.650 |
Why?
| | Cetuximab | 5 | 2021 | 94 | 0.620 |
Why?
| | Flow Cytometry | 5 | 2010 | 1159 | 0.600 |
Why?
| | Peptides, Cyclic | 1 | 2020 | 256 | 0.580 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2024 | 1336 | 0.580 |
Why?
| | Phosphatidylinositol 3-Kinase | 2 | 2022 | 26 | 0.570 |
Why?
| | Salivary Gland Neoplasms | 1 | 2018 | 34 | 0.570 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2013 | 757 | 0.570 |
Why?
| | Chromosomes, Human, Pair 11 | 5 | 2010 | 56 | 0.560 |
Why?
| | Cell Line, Tumor | 14 | 2024 | 3186 | 0.510 |
Why?
| | Hedgehog Proteins | 3 | 2015 | 188 | 0.510 |
Why?
| | Hyaluronan Receptors | 5 | 2020 | 97 | 0.470 |
Why?
| | Veratrum Alkaloids | 2 | 2014 | 19 | 0.450 |
Why?
| | Mutagenicity Tests | 2 | 2009 | 8 | 0.400 |
Why?
| | Mice | 21 | 2024 | 16961 | 0.380 |
Why?
| | Mice, Nude | 8 | 2019 | 682 | 0.380 |
Why?
| | DNA Mutational Analysis | 2 | 2009 | 382 | 0.350 |
Why?
| | Animals | 27 | 2024 | 35391 | 0.340 |
Why?
| | RNA, Messenger | 2 | 2016 | 2708 | 0.330 |
Why?
| | Cell Proliferation | 9 | 2019 | 2373 | 0.320 |
Why?
| | Mutation | 5 | 2018 | 3717 | 0.300 |
Why?
| | Point Mutation | 1 | 2009 | 224 | 0.290 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 1560 | 0.290 |
Why?
| | Antineoplastic Agents | 5 | 2016 | 2046 | 0.280 |
Why?
| | Tumor Microenvironment | 4 | 2022 | 627 | 0.270 |
Why?
| | Smad4 Protein | 2 | 2019 | 38 | 0.260 |
Why?
| | Tumor Cells, Cultured | 5 | 2019 | 943 | 0.240 |
Why?
| | Oxygen | 1 | 2010 | 915 | 0.230 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2017 | 201 | 0.220 |
Why?
| | Receptor, Notch1 | 2 | 2015 | 62 | 0.220 |
Why?
| | Hematopoietic Stem Cells | 2 | 2018 | 382 | 0.210 |
Why?
| | Disease Models, Animal | 6 | 2020 | 4078 | 0.210 |
Why?
| | Signal Transduction | 9 | 2024 | 4931 | 0.210 |
Why?
| | Immunohistochemistry | 3 | 2019 | 1685 | 0.210 |
Why?
| | Sulfones | 2 | 2014 | 108 | 0.200 |
Why?
| | Immunophenotyping | 3 | 2019 | 311 | 0.200 |
Why?
| | Glycine | 2 | 2014 | 165 | 0.200 |
Why?
| | Glycolysis | 1 | 2024 | 315 | 0.200 |
Why?
| | Humans | 34 | 2024 | 129626 | 0.190 |
Why?
| | CHO Cells | 4 | 2010 | 154 | 0.190 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2020 | 958 | 0.190 |
Why?
| | Cricetinae | 4 | 2010 | 279 | 0.190 |
Why?
| | Phosphatidylinositol 3-Kinases | 4 | 2022 | 361 | 0.190 |
Why?
| | Papillomaviridae | 3 | 2019 | 114 | 0.190 |
Why?
| | Caveolin 1 | 1 | 2021 | 19 | 0.190 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 198 | 0.190 |
Why?
| | Ethyl Methanesulfonate | 3 | 2009 | 4 | 0.180 |
Why?
| | Cricetulus | 3 | 2010 | 108 | 0.180 |
Why?
| | DNA Repair | 2 | 2020 | 210 | 0.180 |
Why?
| | Precancerous Conditions | 1 | 2022 | 160 | 0.170 |
Why?
| | Heterografts | 2 | 2019 | 133 | 0.170 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.170 |
Why?
| | Antigens, CD | 2 | 2016 | 487 | 0.160 |
Why?
| | Neoplasms | 2 | 2014 | 2455 | 0.160 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2020 | 132 | 0.160 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 251 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 181 | 0.160 |
Why?
| | Protein Kinase Inhibitors | 2 | 2015 | 887 | 0.160 |
Why?
| | Stem Cell Niche | 1 | 2019 | 53 | 0.160 |
Why?
| | Mouth Neoplasms | 1 | 2019 | 85 | 0.150 |
Why?
| | Neoplasm Proteins | 2 | 2024 | 419 | 0.150 |
Why?
| | Carcinogenesis | 2 | 2018 | 213 | 0.150 |
Why?
| | Neoplasm Transplantation | 2 | 2016 | 256 | 0.150 |
Why?
| | Genetic Heterogeneity | 1 | 2019 | 58 | 0.150 |
Why?
| | Radiotherapy | 1 | 2019 | 185 | 0.150 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 208 | 0.150 |
Why?
| | Chromosome Aberrations | 1 | 2019 | 147 | 0.150 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2018 | 51 | 0.150 |
Why?
| | Mutagens | 2 | 2009 | 17 | 0.150 |
Why?
| | Papillomavirus Infections | 2 | 2019 | 297 | 0.140 |
Why?
| | Radiation Tolerance | 2 | 2016 | 98 | 0.140 |
Why?
| | DNA Damage | 1 | 2020 | 384 | 0.140 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2016 | 326 | 0.140 |
Why?
| | Gene Deletion | 1 | 2019 | 382 | 0.140 |
Why?
| | Wnt Signaling Pathway | 1 | 2018 | 170 | 0.130 |
Why?
| | Cell Communication | 1 | 2018 | 301 | 0.130 |
Why?
| | Cell Cycle | 1 | 2020 | 588 | 0.130 |
Why?
| | Retinal Dehydrogenase | 1 | 2016 | 30 | 0.130 |
Why?
| | Receptor, EphB4 | 1 | 2016 | 36 | 0.130 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2016 | 398 | 0.130 |
Why?
| | Small Molecule Libraries | 1 | 2017 | 86 | 0.130 |
Why?
| | Corynebacterium | 1 | 2017 | 48 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 441 | 0.130 |
Why?
| | Corynebacterium Infections | 1 | 2017 | 40 | 0.130 |
Why?
| | Neoplasms, Experimental | 1 | 2017 | 170 | 0.130 |
Why?
| | Immunotherapy | 1 | 2020 | 596 | 0.130 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2016 | 101 | 0.120 |
Why?
| | Spheroids, Cellular | 1 | 2016 | 77 | 0.120 |
Why?
| | Proto-Oncogene Proteins | 3 | 2014 | 636 | 0.120 |
Why?
| | Oncogene Proteins | 1 | 2015 | 55 | 0.120 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2015 | 56 | 0.120 |
Why?
| | Cadherins | 1 | 2016 | 190 | 0.120 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2015 | 35 | 0.120 |
Why?
| | Recurrence | 1 | 2018 | 1011 | 0.120 |
Why?
| | Gene Dosage | 1 | 2015 | 143 | 0.120 |
Why?
| | Cell Division | 1 | 2016 | 796 | 0.110 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 168 | 0.110 |
Why?
| | Stromal Cells | 1 | 2014 | 106 | 0.110 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 427 | 0.110 |
Why?
| | Cytokines | 2 | 2019 | 2021 | 0.110 |
Why?
| | Melanoma | 1 | 2020 | 730 | 0.110 |
Why?
| | Cell Line | 2 | 2009 | 2784 | 0.110 |
Why?
| | Receptor, Notch2 | 1 | 2013 | 15 | 0.100 |
Why?
| | Receptor Cross-Talk | 1 | 2013 | 21 | 0.100 |
Why?
| | Gonanes | 1 | 2013 | 27 | 0.100 |
Why?
| | Sarcoma | 1 | 2015 | 176 | 0.100 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2018 | 576 | 0.100 |
Why?
| | Alphapapillomavirus | 1 | 2013 | 39 | 0.100 |
Why?
| | ras Proteins | 1 | 2013 | 144 | 0.100 |
Why?
| | Thy-1 Antigens | 2 | 2009 | 11 | 0.100 |
Why?
| | Gene Silencing | 1 | 2013 | 190 | 0.100 |
Why?
| | Pyrazoles | 1 | 2015 | 404 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2015 | 752 | 0.090 |
Why?
| | Pyrimidines | 1 | 2015 | 459 | 0.090 |
Why?
| | Female | 11 | 2024 | 68734 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1687 | 0.090 |
Why?
| | CD24 Antigen | 1 | 2010 | 20 | 0.090 |
Why?
| | Transcriptome | 1 | 2016 | 876 | 0.090 |
Why?
| | Disease Progression | 1 | 2018 | 2627 | 0.090 |
Why?
| | Blotting, Western | 1 | 2013 | 1206 | 0.080 |
Why?
| | Mice, Inbred NOD | 2 | 2023 | 587 | 0.080 |
Why?
| | Epithelial-Mesenchymal Transition | 3 | 2019 | 201 | 0.080 |
Why?
| | Dimethyl Sulfoxide | 1 | 2010 | 41 | 0.080 |
Why?
| | Free Radical Scavengers | 1 | 2010 | 82 | 0.080 |
Why?
| | Alkylating Agents | 1 | 2009 | 24 | 0.080 |
Why?
| | Asbestos | 1 | 2009 | 28 | 0.080 |
Why?
| | Mutagenesis | 1 | 2010 | 181 | 0.080 |
Why?
| | Gamma Rays | 1 | 2009 | 54 | 0.080 |
Why?
| | Cell Hypoxia | 1 | 2010 | 234 | 0.080 |
Why?
| | Clone Cells | 1 | 2009 | 262 | 0.080 |
Why?
| | Apoptosis | 4 | 2019 | 2492 | 0.080 |
Why?
| | Computational Biology | 1 | 2013 | 596 | 0.080 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1049 | 0.070 |
Why?
| | Rabbits | 1 | 2010 | 779 | 0.070 |
Why?
| | Cell Cycle Proteins | 3 | 2020 | 584 | 0.070 |
Why?
| | Keratinocytes | 2 | 2022 | 243 | 0.070 |
Why?
| | Colorectal Neoplasms | 1 | 2015 | 749 | 0.070 |
Why?
| | Glycosylphosphatidylinositols | 1 | 2007 | 11 | 0.070 |
Why?
| | Transfection | 1 | 2009 | 915 | 0.070 |
Why?
| | Cell Survival | 1 | 2010 | 1076 | 0.070 |
Why?
| | Genetic Markers | 1 | 2007 | 336 | 0.060 |
Why?
| | Skin Neoplasms | 1 | 2013 | 829 | 0.060 |
Why?
| | Fanconi Anemia | 1 | 2024 | 10 | 0.060 |
Why?
| | Maximum Tolerated Dose | 2 | 2015 | 193 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2342 | 0.060 |
Why?
| | BRCA2 Protein | 1 | 2024 | 54 | 0.060 |
Why?
| | BRCA1 Protein | 1 | 2024 | 66 | 0.060 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1282 | 0.050 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2024 | 70 | 0.050 |
Why?
| | RNA Interference | 2 | 2016 | 450 | 0.050 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 90 | 0.050 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2024 | 124 | 0.050 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2022 | 65 | 0.050 |
Why?
| | Time Factors | 2 | 2010 | 6555 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 232 | 0.050 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 1 | 2020 | 23 | 0.040 |
Why?
| | Feedback, Physiological | 1 | 2020 | 76 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2024 | 1207 | 0.040 |
Why?
| | Prognosis | 2 | 2019 | 3774 | 0.040 |
Why?
| | Heat-Shock Proteins | 1 | 2019 | 136 | 0.040 |
Why?
| | Hyaluronic Acid | 1 | 2020 | 216 | 0.040 |
Why?
| | Transplantation, Heterologous | 1 | 2018 | 192 | 0.040 |
Why?
| | Molecular Chaperones | 1 | 2019 | 182 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2019 | 313 | 0.040 |
Why?
| | Biomarkers | 2 | 2019 | 3968 | 0.040 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 399 | 0.040 |
Why?
| | Monocytes | 1 | 2020 | 553 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2018 | 481 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2016 | 32 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1445 | 0.030 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 45 | 0.030 |
Why?
| | Gene Expression | 2 | 2015 | 1465 | 0.030 |
Why?
| | Male | 6 | 2020 | 63670 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2016 | 317 | 0.030 |
Why?
| | Tumor Burden | 1 | 2016 | 286 | 0.030 |
Why?
| | Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.030 |
Why?
| | Jagged-1 Protein | 1 | 2015 | 23 | 0.030 |
Why?
| | Gene Duplication | 1 | 2015 | 67 | 0.030 |
Why?
| | Lamin Type A | 1 | 2015 | 48 | 0.030 |
Why?
| | Phosphorylation | 1 | 2019 | 1713 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1872 | 0.030 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2014 | 23 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 37 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 698 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2016 | 591 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2015 | 646 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 213 | 0.030 |
Why?
| | Side-Population Cells | 1 | 2013 | 8 | 0.030 |
Why?
| | alpha Catenin | 1 | 2013 | 12 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 391 | 0.030 |
Why?
| | Cell Dedifferentiation | 1 | 2013 | 30 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 273 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 374 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 81 | 0.030 |
Why?
| | Sequence Deletion | 1 | 2013 | 179 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2015 | 611 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 259 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2018 | 2881 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2013 | 318 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 787 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 840 | 0.020 |
Why?
| | Middle Aged | 3 | 2019 | 31136 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2015 | 10219 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2011 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1592 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 827 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 4894 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2015 | 1125 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2015 | 1366 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2128 | 0.020 |
Why?
| | Aged | 2 | 2019 | 22061 | 0.020 |
Why?
| | Fusion Regulatory Protein-1 | 1 | 2007 | 1 | 0.020 |
Why?
| | Tetraspanin 24 | 1 | 2007 | 7 | 0.020 |
Why?
| | Hybrid Cells | 1 | 2007 | 50 | 0.020 |
Why?
| | Mitomycin | 1 | 2006 | 32 | 0.020 |
Why?
| | MicroRNAs | 1 | 2013 | 679 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1647 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2006 | 76 | 0.020 |
Why?
| | Cross-Linking Reagents | 1 | 2006 | 205 | 0.020 |
Why?
| | Organometallic Compounds | 1 | 2006 | 106 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2512 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1035 | 0.010 |
Why?
| | Adult | 2 | 2015 | 35599 | 0.010 |
Why?
| | Young Adult | 1 | 2014 | 12455 | 0.010 |
Why?
|
|
Keysar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|